Q1 EPS Forecast for Voyager Therapeutics Boosted by Analyst

Voyager Therapeutics, Inc. (NASDAQ:VYGR) – Stock analysts at HC Wainwright lifted their Q1 2025 earnings per share (EPS) estimates for shares of Voyager Therapeutics in a research note issued on Thursday, March 13th. HC Wainwright analyst P. Trucchio now expects that the company will post earnings per share of ($0.21) for the quarter, up from their previous forecast of ($0.30). HC Wainwright currently has a “Buy” rating and a $30.00 price objective on the stock. The consensus estimate for Voyager Therapeutics’ current full-year earnings is ($0.91) per share. HC Wainwright also issued estimates for Voyager Therapeutics’ Q2 2025 earnings at ($0.22) EPS, Q3 2025 earnings at ($0.20) EPS, Q4 2025 earnings at ($0.23) EPS, FY2025 earnings at ($0.86) EPS, FY2026 earnings at ($1.04) EPS, FY2027 earnings at ($1.07) EPS, FY2028 earnings at ($1.47) EPS and FY2029 earnings at ($1.40) EPS.

A number of other research firms also recently issued reports on VYGR. StockNews.com downgraded Voyager Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, December 13th. Wells Fargo & Company set a $10.00 target price on Voyager Therapeutics and gave the company an “overweight” rating in a research report on Wednesday, March 12th. Citigroup started coverage on Voyager Therapeutics in a research report on Monday, December 2nd. They set a “buy” rating and a $12.00 price target on the stock. Wedbush reissued an “outperform” rating on shares of Voyager Therapeutics in a research report on Wednesday, March 12th. Finally, Canaccord Genuity Group lowered their price target on Voyager Therapeutics from $14.00 to $12.00 and set a “buy” rating on the stock in a research report on Thursday, March 13th. One research analyst has rated the stock with a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Buy” and an average target price of $14.86.

Voyager Therapeutics Stock Performance

NASDAQ:VYGR opened at $3.88 on Monday. The stock’s 50-day simple moving average is $4.75 and its 200 day simple moving average is $5.78. The company has a market cap of $214.20 million, a P/E ratio of 5.46 and a beta of 0.99. Voyager Therapeutics has a 52-week low of $3.56 and a 52-week high of $10.66.

Voyager Therapeutics (NASDAQ:VYGR) last released its earnings results on Tuesday, March 11th. The company reported ($0.59) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.24). The company had revenue of $4.39 million during the quarter, compared to analyst estimates of $16.58 million. Voyager Therapeutics had a net margin of 15.80% and a return on equity of 8.33%. During the same period in the prior year, the firm posted $1.25 EPS.

Institutional Investors Weigh In On Voyager Therapeutics

A number of institutional investors have recently made changes to their positions in VYGR. Erste Asset Management GmbH bought a new stake in shares of Voyager Therapeutics during the third quarter worth approximately $6,192,000. Vestal Point Capital LP boosted its holdings in shares of Voyager Therapeutics by 151.0% during the fourth quarter. Vestal Point Capital LP now owns 1,230,000 shares of the company’s stock worth $6,974,000 after acquiring an additional 740,000 shares during the period. Farallon Capital Management LLC boosted its holdings in shares of Voyager Therapeutics by 12.2% during the fourth quarter. Farallon Capital Management LLC now owns 2,570,700 shares of the company’s stock worth $14,576,000 after acquiring an additional 278,700 shares during the period. Dimensional Fund Advisors LP boosted its holdings in shares of Voyager Therapeutics by 24.9% during the fourth quarter. Dimensional Fund Advisors LP now owns 1,380,615 shares of the company’s stock worth $7,828,000 after acquiring an additional 275,571 shares during the period. Finally, Raymond James Financial Inc. bought a new stake in shares of Voyager Therapeutics during the fourth quarter worth approximately $746,000. Institutional investors own 48.03% of the company’s stock.

Insider Transactions at Voyager Therapeutics

In other news, COO Robin Swartz sold 6,500 shares of the business’s stock in a transaction that occurred on Monday, December 23rd. The stock was sold at an average price of $5.65, for a total transaction of $36,725.00. Following the completion of the sale, the chief operating officer now owns 112,328 shares in the company, valued at $634,653.20. The trade was a 5.47 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders sold a total of 10,778 shares of company stock worth $58,548 over the last quarter. Company insiders own 4.53% of the company’s stock.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.